15
May
2015
More than Moderna: Who’s Who in mRNA Therapeutics?
Biotech doesn’t usually make for must-see TV. It scares most people. Something must be up if a biotech company can get extended air time on television. Cambridge, Mass.-based Moderna Therapeutics captured more than its share of attention this week when it succeeded Elon Musk’s Mars exploration company as the “No. 1 Disruptor” in corporate America by CNBC. Many in biotech... Read More
Share:
4
May
2015
What’s Real, and What’s Not Yet, in Digital Health?
The late, great columnist Molly Ivins once said there are three ways to evaluate a politician. First, look at the record. Second, look at the record. Third, look at the record. Notice the lack of emphasis on what the politician says. Actions speak. Digital health, for some time, has been one of those areas long on talk and short on... Read More
Share:
15
Apr
2015
Who Should Biotech Pros Follow on Twitter?
Many people in biotech are still afraid of Twitter, even as it has accumulated more than 280 million users. Drug companies want to advertise to patients and doctors on social media, but they’re afraid the FDA will slap them for misleading promotions. They want to engage with investors, but they’re afraid someone (rightly or wrongly) will question their clinical trial... Read More
Share:
20
Feb
2015
Five Things to Watch at Next Week’s Big Genomics Show
This is the cold, dreary, snowy time of year when all the geeky kids in genomics flock to a remote island off the Florida Gulf Coast. The boys, and they are mostly boys, will hear a lot of marketing hype about the whiz-bang new tools being developed for biology. They’ll hear a few nitty-gritty technical talks from scientists doing exciting... Read More
Share:
11
Feb
2015
Intelligent MDx, Maker of Molecular Diagnostics That Raised $40M, Shuts Down
Intelligent MDx, the Waltham, Mass.-based maker of several molecular diagnostic tests for infectious disease that run on instruments from Abbott Laboratories, has laid off its staff and is winding down operations, the Timmerman Report has learned from sources close to the situation.
Share:
9
Feb
2015
Cellular Dynamics Tracks Down ‘Superdonors’ for Cell Therapy
One of the big bugaboos in transplant medicine is immune rejection. Whether you’re talking about bone marrow, liver, or kidneys—getting a genetic match to avoid immune rejection is generally not trivial, and it’s critical to making a transplant successful. It could get easier. There are a small number of people on earth who have the right HLA (human leukocyte antigen)... Read More
Share:
4
Feb
2015
Third Rock’s Obesity Hopeful, Ember Therapeutics, Closes Down
Ember Therapeutics, a biotech startup with big money, prominent founders, and a novel idea for fighting obesity, shut down operations a few weeks ago, the Timmerman Report has learned.
Share:
2
Feb
2015
The Merck Exodus: Where Are the Talented People Going?
One of the great talent migrations in pharmaceutical R&D history is going on right now. Merck, the drugmaker with a proud scientific tradition, has seen a huge wave of departures from its senior R&D ranks the past two years. The exodus has turned into a recruiting bonanza for a range of biotech startups, venture firms, consultancies, and competitors. The exits flung open... Read More
Share:
